Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | WRN | Q14191 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028333 | 0.91 | ABL1 (0.37) | CCR1CCR2PRKCA | |
| SCHEMBL1027865 | 0.87 | ALDH1A1 (0.35) | CCR1CCR2ALDH1A1CYP1A2HPGD | |
| SCHEMBL1027562 | 0.80 | SLC25A5 (0.36) | — | |
| SCHEMBL1026541 | 0.79 | NPC1 (0.42) | ALDH1A1HPGDCYP2C19 | |
| SCHEMBL1026383 | 0.78 | SLC6A1 (0.31) | CCR1CCR2 | |
| SCHEMBL1028803 | 0.78 | PPM1B (0.35) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL1029070 | 0.78 | GRM4 (0.47) | HSD17B10ALDH1A1HPGD | |
| SCHEMBL1025474 | 0.77 | TAAR1 (0.35) | HSD17B10 | |
| SCHEMBL1026621 | 0.77 | GSK3A (0.41) | HSD17B10ALDH1A1HPGD | |
| SCHEMBL1028998 | 0.76 | POLB (0.45) | ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479669-B1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | TOSOH CORP (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7645889-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7381742-B2 | Optically active polymaleimide derivatives and process for their production | TOSOH CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-06-14 | — | — | US | disclosed |
| US-7186750-B2 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | TOSOH CORPORATION (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1479669-A1 | Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography | Tosoh Corporation (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080230482-A1 | Optically active polymaleimide derivatives and process for their production | CYBA, COASY, MEP1B | CCR1 4820/4885CCR2 4559/4885HSD17B10 1179/4885 |
| US-20040235937-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, CYBA | CCR1 4842/4885CCR2 4743/4885HSD17B10 2109/4885 |
| US-20070131616-A1 | Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them | MACF1, MEP1B, ACMSD | CCR1 4850/4885CCR2 4731/4885HSD17B10 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.